TL-532, a novel rationally designed TLR3 agonist, induces tumor-specific apoptosis, immune simulation, life-long anti-tumor auto-vaccination, and reverses resistance to immune checkpoint inhibitors
OTS – October 2022, Phoenix (USA) – M Bonnin
OTS – October 2022, Phoenix (USA) – M Bonnin
IRCI 15-17 June 2022 Lyon – M Bonnin
AACR 8-13 Avril 2022 New Orleans – S Thierry
ESMO – December 2021 – Presented by Dr Bettina Werle
OTS – September 2021 – Dr Marc Bonnin
OTS – September 2021 – Dr Sylvain Thierry
Recent Comments